Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Eli Lilly's Mounjaro (Tirzepatide), a dual GIP and GLP-1 receptor agonist, has launched in India, generating buzz as a weight ...

Long-term use of tirzepatide shows sustained and significant weight loss in adults with overweight or obesity.

The study, led by Dr Luca Busetto from the University of Padova in Italy and colleagues from Eli Lilly and Company that ...

A once-weekly dose of tirzepatide (Mounjaro) can lead to significant, sustained weight loss for up to 3 years in adults with ...

Taking tirzepatide drug once a week may produce clinically meaningful and sustained weight loss for at least 3 years in ad ...

Patients with type 2 diabetes who switched to tirzepatide rather than escalating their dulaglutide dosage had greater weight ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New ...

For adults struggling with weight, a weekly injection of tirzepatide offers real hope. Recent findings presented at the European Congress on Obesity (ECO) in Malaga, Spain, reveal that the drug ...